Clinical Report: The Impact of Unadjusted Confounding on the Link Between Clonal Hematopoiesis and Heart Failure Following Cancer Treatment
Overview
This report evaluates the potential bias introduced by unadjusted confounding factors in the association between clonal hematopoiesis of indeterminate potential (CHIP) and heart failure risk following cancer therapy.
Background
Clonal hematopoiesis of indeterminate potential (CHIP) has been linked to an increased risk of heart failure in patients undergoing cancer treatment. Understanding the impact of confounding factors is crucial for accurately interpreting the relationship between CHIP and heart failure.
Data Highlights
No numerical data presented in the source material.
Key Findings
The original study reported a subdistribution hazard ratio (sHR) of 1.26 for the association between CHIP and heart failure.
Unadjusted confounding factors such as diabetes, HIV infection, obesity, chronic kidney disease, and cirrhosis were not accounted for in the original analysis.
The E-value calculated was 1.83, indicating the strength of association needed for an unadjusted confounder to nullify the reported association.
The E-value of 1.83 was lower than the strength of associations between adjusted covariates and heart failure.
Substantial bias from unadjusted confounding cannot be excluded based on the analysis.
Clinical Implications
Clinicians should be aware of the limitations in the association between CHIP and heart failure due to unadjusted confounding factors.
Conclusion
The association between CHIP and heart failure following cancer therapy may be influenced by unadjusted confounding factors.
